company background image
A006620 logo

DongKoo Bio & Pharma KOSDAQ:A006620 Stock Report

Last Price

₩6.17k

Market Cap

₩170.4b

7D

2.2%

1Y

-0.5%

Updated

27 Mar, 2024

Data

Company Financials

DongKoo Bio & Pharma Co., Ltd.

KOSDAQ:A006620 Stock Report

Market Cap: ₩170.4b

A006620 Stock Overview

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea.

A006620 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends2/6

DongKoo Bio & Pharma Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DongKoo Bio & Pharma
Historical stock prices
Current Share Price₩6,170.00
52 Week High₩6,720.00
52 Week Low₩4,615.00
Beta0.84
1 Month Change8.25%
3 Month Change9.01%
1 Year Change-0.48%
3 Year Change-43.91%
5 Year Change-9.49%
Change since IPO-51.92%

Recent News & Updates

We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Mar 27
We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Recent updates

We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Mar 27
We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Shareholder Returns

A006620KR PharmaceuticalsKR Market
7D2.2%6.0%3.8%
1Y-0.5%28.8%13.0%

Return vs Industry: A006620 underperformed the KR Pharmaceuticals industry which returned 28.8% over the past year.

Return vs Market: A006620 underperformed the KR Market which returned 13% over the past year.

Price Volatility

Is A006620's price volatile compared to industry and market?
A006620 volatility
A006620 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement4.8%
Market Average Movement5.3%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A006620 has not had significant price volatility in the past 3 months.

Volatility Over Time: A006620's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1970355Cho Yong-Junhttps://www.dongkoo.com

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs.

DongKoo Bio & Pharma Co., Ltd. Fundamentals Summary

How do DongKoo Bio & Pharma's earnings and revenue compare to its market cap?
A006620 fundamental statistics
Market cap₩170.44b
Earnings (TTM)₩11.81b
Revenue (TTM)₩215.69b

14.4x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A006620 income statement (TTM)
Revenue₩215.69b
Cost of Revenue₩83.61b
Gross Profit₩132.08b
Other Expenses₩120.26b
Earnings₩11.81b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)427.59
Gross Margin61.24%
Net Profit Margin5.48%
Debt/Equity Ratio38.0%

How did A006620 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

45%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.